Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 10/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8962619 | 0.86 | ALDH1A1 (0.69) | CRHBPCRHR2ALDH1A1MAPTTDP1 | |
| SCHEMBL6132129 | 0.86 | ALDH1A1 (0.69) | CRHBPCRHR2ALDH1A1MAPTTDP1 | |
| SCHEMBL26496466 | 0.86 | ALDH1A1 (0.69) | CRHBPCRHR2ALDH1A1MAPTTDP1 | |
| SCHEMBL10505373 | 0.86 | ALDH1A1 (0.69) | CRHBPCRHR2ALDH1A1MAPTTDP1 | |
| SCHEMBL9348638 | 0.86 | ALDH1A1 (0.69) | CRHBPCRHR2ALDH1A1MAPTTDP1 | |
| SCHEMBL28465359 | 0.81 | ALDH1A1 (0.54) | ALDH1A1MAPTTDP1MAPK1L3MBTL1 | |
| SCHEMBL26934198 | 0.80 | ALDH1A1 (0.58) | CRHBPCRHR2ALDH1A1MAPTTDP1 | |
| SCHEMBL26934190 | 0.80 | ALDH1A1 (0.58) | CRHBPCRHR2ALDH1A1MAPTTDP1 | |
| SCHEMBL28705330 | 0.78 | KMT2A (0.50) | ALDH1A1MAPTTDP1HTTKDM4E | |
| SCHEMBL5137640 | 0.78 | MAPT (0.69) | CRHBPCRHR2ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102461-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | AIKIUM INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-1504094-A2 | PEPTIDE COMPOUNDS AND THEIR USE AS PROTEASE SUBSTRATES | Pharmacia Corporation (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20040018561-A1 | Peptide compounds and their use as protease substrates | PHARMACIA CORPORATION | 2004-01-29 | — | — | US | disclosed |
| WO-2003095475-A2 | PEPTIDE COMPOUNDS AND THEIR USE AS PROTEASE SUBSTRATES | PHARMACIA CORPORATION (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040018561-A1 | Peptide compounds and their use as protease substrates | MMP3, MMP25, MMP11 | CRHBP 969/4885CRHR2 3216/4885ALDH1A1 3443/4885 |
| US-20260102461-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | MAX, CRYZ, STAMBP | CRHBP 127/4885CRHR2 4016/4885ALDH1A1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.